These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10449288)

  • 61. Antiretroviral therapy in human immunodeficiency virus-infected individuals.
    Spooner KM
    Adv Intern Med; 1998; 43():373-402. PubMed ID: 9506188
    [No Abstract]   [Full Text] [Related]  

  • 62. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.
    Dybul M; Chun TW; Ward DJ; Hertogs K; Larder B; Fox CH; Orenstein JM; Baird BF; Li Y; Green LG; Engel D; Liu S; Mican JM; Fauci AS
    J Infect Dis; 2000 Apr; 181(4):1273-9. PubMed ID: 10836864
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.
    Dornadula G; Zhang H; VanUitert B; Stern J; Livornese L; Ingerman MJ; Witek J; Kedanis RJ; Natkin J; DeSimone J; Pomerantz RJ
    JAMA; 1999 Nov; 282(17):1627-32. PubMed ID: 10553788
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.
    Clerici M; Seminari E; Suter F; Castelli F; Pan A; Biasin M; Colombo F; Trabattoni D; Maggiolo F; Carosi G; Maserati R
    AIDS; 2000 Jan; 14(2):109-16. PubMed ID: 10708280
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
    Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
    AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
    Dieleman JP; Jambroes M; Gyssens IC; Sturkenboom MC; Stricker BH; Mulder WM; de Wolf F; Weverling GJ; Lange JM; Reiss P; Brinkman K;
    AIDS; 2002 Mar; 16(5):737-45. PubMed ID: 11964530
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Determinants of increased energy expenditure in HIV-infected women.
    Grinspoon S; Corcoran C; Miller K; Wang E; Hubbard J; Schoenfeld D; Anderson E; Basgoz N; Klibanski A
    Am J Clin Nutr; 1998 Sep; 68(3):720-5. PubMed ID: 9734753
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.
    Grabar S; Le Moing V; Goujard C; Leport C; Kazatchkine MD; Costagliola D; Weiss L
    Ann Intern Med; 2000 Sep; 133(6):401-10. PubMed ID: 10975957
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
    Maia BS; Engelson ES; Wang J; Kotler DP
    Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia.
    Ross L; Johnson M; DeMasi R; Liao Q; Graham N; Shaefer M; St Clair M
    AIDS; 2000 May; 14(7):813-9. PubMed ID: 10839589
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
    Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
    AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.